Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Center for Forensic Science Research and Education, Fredric Rieders Family Foundation, Willow Grove, PA, 19090, USA.
Arch Toxicol. 2024 Sep;98(9):2999-3018. doi: 10.1007/s00204-024-03774-7. Epub 2024 Jun 14.
2-Benzylbenzimidazole 'nitazene' opioids are presenting a growing threat to public health. Although various nitazenes were previously studied, systematic comparisons of the effects of different structural modifications to the 2-benzylbenzimidazole core structure on μ-opioid receptor (MOR) activity are limited. Here, we assessed in vitro structure-activity relationships of 9 previously uncharacterized nitazenes alongside known structural analogues. Specifically, we focused on MOR activation by 'ring' substituted analogues (i.e., N-pyrrolidino and N-piperidinyl modifications), 'desnitazene' analogues (lacking the 5-nitro group), and N-desethyl analogues. The results from two in vitro MOR activation assays (β-arrestin 2 recruitment and inhibition of cAMP accumulation) showed that 'ring' modifications overall yield highly active drugs. With the exception of 4'-OH analogues (which are metabolites), N-pyrrolidino substitutions were generally more favorable for MOR activation than N-piperidine substitutions. Furthermore, removal of the 5-nitro group on the benzimidazole ring consistently caused a pronounced decrease in potency. The N-desethyl modifications showed important MOR activity, and generally resulted in a slightly lowered potency than comparator nitazenes. Intriguingly, N-desethyl isotonitazene was the exception and was consistently more potent than isotonitazene. Complementing the in vitro findings and demonstrating the high harm potential associated with many of these compounds, we describe 85 forensic cases from North America and the United Kingdom involving etodesnitazene, N-desethyl etonitazene, N-desethyl isotonitazene, N-pyrrolidino metonitazene, and N-pyrrolidino protonitazene. The low-to-sub ng/mL blood concentrations observed in most cases underscore the drugs' high potencies. Taken together, by bridging pharmacology and case data, this study may aid to increase awareness and guide legislative and public health efforts.
2-苄基苯并咪唑类“硝甲西泮”类阿片类药物对公众健康构成的威胁日益严重。尽管之前对各种硝甲西泮类药物进行了研究,但对 2-苄基苯并咪唑核心结构的不同结构修饰对μ-阿片受体(MOR)活性的影响进行系统比较的研究还很有限。在这里,我们评估了 9 种以前未表征的硝甲西泮类药物以及已知结构类似物的体外结构-活性关系。具体来说,我们专注于“环”取代类似物(即 N-吡咯烷和 N-哌啶基修饰)、“去硝甲西泮”类似物(缺乏 5-硝基)和 N-去乙基类似物对 MOR 的激活作用。两种体外 MOR 激活测定法(β- arrestin 2 募集和 cAMP 积累抑制)的结果表明,“环”修饰总体上产生了高活性药物。除了 4'-OH 类似物(是代谢物)之外,N-吡咯烷取代通常比 N-哌啶取代更有利于 MOR 的激活。此外,苯并咪唑环上的 5-硝基基团的去除会导致效力明显降低。N-去乙基修饰显示出重要的 MOR 活性,并且通常比比较硝甲西泮的效力略低。有趣的是,N-去乙基异硝甲西泮是个例外,它始终比异硝甲西泮更有效。补充了体外研究结果,并证明了这些化合物中的许多都具有很高的危害性,我们描述了来自北美和英国的 85 例法医案例,涉及乙硝西泮、N-去乙基乙硝西泮、N-去乙基异硝甲西泮、N-吡咯烷甲硝西泮和 N-吡咯烷质子硝甲西泮。大多数情况下观察到的低至亚 ng/mL 的血液浓度突显了这些药物的高效力。总之,通过将药理学和案例数据联系起来,这项研究可能有助于提高认识,并为立法和公共卫生工作提供指导。